The European Commission approved Novo Nordisk A/S’ (NYSE:NVO) Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related comorbidity.
The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states.
The approval covers adults with a body mass index (BMI) of at least 30 kg/m² or at least 27 kg/m² with one or more weight-related comorbidities, to be used alongside a reduced-calorie diet and increased physical activity.
Read Next
News
